KHN702, a Novel Selective hNav1.8 Inhibitor for Pain Therapy (S38.002)

Key Points

• The study aims to assess the effectiveness and safety of KHN702 for pain management.
• Randomized trial design to evaluate the intervention
• Participants allocated to receive KHN702 or placebo
• KHN702 demonstrated significant pain relief compared to placebo.
• Adverse effects were minimal, suggesting a favorable safety profile.